GlassScriptPhysician profile
Raymond G Lau
NPI 1568649135
$3,132.38
in general payments reported to CMS, 2019-2025
28 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.75 · 2020: $301 · 2021: $614 · 2022: $493 · 2023: $665 · 2024: $281 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $625.00 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $380.48 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $299.52 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $218.65 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.09 | 2020-2023 | Synjardy |
| Corcept Therapeutics | $178.83 | 2021-2025 | Korlym |
| Abbott Laboratories | $161.02 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $147.73 | 2020-2024 | Mounjaro, Zepbound |
| Alexion Pharmaceuticals, INC. | $127.95 | 2022-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $96.26 | 2021-2025 | Unithroid |
| Intra-Sana Laboratories | $86.65 | 2021-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Insulet Corporation | $62.01 | 2023-2024 | Omnipod |
| Medtronic Minimed, INC. | $61.44 | 2020 | |
| Tandem Diabetes Care, INC. | $61.32 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Standard Bariatrics, INC. | $50.23 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.04 | 2023-2025 | |
| Amgen INC. | $42.68 | 2022-2025 | Evenity, Prolia |
| Cequr Corporation | $39.71 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $38.63 | 2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $37.27 | 2025 | Rezdiffra |
| Avanos Medical | $29.76 | 2019 | |
| Pfizer INC. | $23.99 | 2023 | |
| Tolmar, INC. | $21.81 | 2024 | |
| Ascensia Diabetes Care US INC. | $21.62 | 2023 | |
| Currax Pharmaceuticals LLC | $16.80 | 2025 | Contrave |
| Ultragenyx Pharmaceutical INC. | $14.33 | 2020 | |
| Vistapharm, INC. | $14.12 | 2021 | |
| Ibsa Pharma INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.